Evidence map›Paper›PMID 21692504›Full record

ArticleJournal of the American Chemical Society2011

A substrate-free activity-based protein profiling screen for the discovery of selective PREPL inhibitors.

Anna Mari Lone, Daniel A Bachovchin, David B Westwood, Anna E Speers, Timothy P Spicer, Virneliz Fernandez-Vega, Peter Chase, Peter S Hodder, Hugh Rosen, Benjamin F Cravatt and 1 more

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. PREPL deficiency: delineation of the phenotype and development of a functional blood assay.Genetics in medicine : official journal of the American College of Medical Genetics · 2018
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Anna Mari LoneDepartment of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts 02138, USA.
Daniel A Bachovchin
David B Westwood
Anna E Speers
Timothy P Spicer
Virneliz Fernandez-Vega
Peter Chase
Peter S Hodder
Hugh Rosen
Benjamin F Cravatt
Alan Saghatelian
Scripps Research Institute · USHarvard University · US

Funding

UHTS Implementation(Florida)U54MH084512 · NIMH · SCRIPPS RESEARCH INSTITUTE, THE · PI ROSEN, HUGH · 2008 to 2013
$89.2M
Training in Molecular, Cellular, and Chemical BiologyT32GM007598 · NIGMS · HARVARD UNIVERSITY · PI DULAC, CATHERINE · 1985 to 2019
$16.2M
Chemical Probes for Metabolic Pathway Discovery in Human DiseaseR01CA132630 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI CRAVATT, BENJAMIN F · 2007 to 2018
$5.1M
Discovery metabolite profiling of the prolyl peptidasesDP2OD002374 · OD · HARVARD UNIVERSITY · PI SAGHATELIAN, ALAN · 2007 to 2009
$2.6M
NCI NIH HHS CA132630NCI NIH HHS R01 CA132630NIGMS NIH HHS GM007598NIGMS NIH HHS T32 GM007598NIH HHS 1DP2OD002374NIH HHS DP2 OD002374NIMH NIH HHS MH084512NIMH NIH HHS U54 MH084512
6 · The paper itself

Abstract

Peptidases play vital roles in physiology through the biosynthesis, degradation, and regulation of peptides. Prolyl endopeptidase-like (PREPL) is a newly described member of the prolyl peptidase family, with significant homology to mammalian prolyl endopeptidase and the bacterial peptidase oligopeptidase B. The biochemistry and biology of PREPL are of fundamental interest due to this enzyme's homology to the biomedically important prolyl peptidases and its localization in the central nervous system. Furthermore, genetic studies of patients suffering from hypotonia-cystinuria syndrome (HCS) have revealed a deletion of a portion of the genome that includes the PREPL gene. HCS symptoms thought to be caused by lack of PREPL include neuromuscular and mild cognitive deficits. A number of complementary approaches, ranging from biochemistry to genetics, will be required to understand the biochemical, cellular, physiological, and pathological mechanisms regulated by PREPL. We are particularly interested in investigating physiological substrates and pathways controlled by PREPL. Here, we use a fluorescence polarization activity-based protein profiling (fluopol-ABPP) assay to discover selective small-molecule inhibitors of PREPL. Fluopol-ABPP is a substrate-free approach that is ideally suited for studying serine hydrolases for which no substrates are known, such as PREPL. After screening over 300,000 compounds using fluopol-ABPP, we employed a number of secondary assays to confirm assay hits and characterize a group of 3-oxo-1-phenyl-2,3,5,6,7,8-hexahydroisoquinoline-4-carbonitrile and 1-alkyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile PREPL inhibitors that are able to block PREPL activity in cells. Moreover, when administered to mice, 1-isobutyl-3-oxo-3,5,6,7-tetrahydro-2H-cyclopenta[c]pyridine-4-carbonitrile distributes to the brain, indicating that it may be useful for in vivo studies. The application of fluopol-ABPP has led to the first reported PREPL inhibitors, and these inhibitors will be of great value in studying the biochemistry of PREPL and in eventually understanding the link between PREPL and HCS.

Indexed as

Drug DiscoveryHigh-Throughput Screening AssaysAnimalsCell Line, TumorDose-Response Relationship, DrugEnzyme InhibitorsFluorescence PolarizationGene Expression ProfilingMiceMice, Inbred C57BLMolecular StructureProlyl OligopeptidasesSerine EndopeptidasesStructure-Activity RelationshipEnzyme InhibitorsProlyl OligopeptidasesSerine Endopeptidases

Identifiers

PMID21692504
PMCPMC3145007
OpenAlexW2013273907

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.